Zollinger‑Ellison Syndrome – Malignant Type
Overview
Zollinger‑Ellison syndrome (ZES) is a rare condition in which one or more gastrin‑producing neuroendocrine tumors (gastrinomas) form in the pancreas or duodenum. The malignant form refers to tumors that have spread beyond their site of origin (i.e., they are invasive or metastasized). These tumors secrete large amounts of gastrin, a hormone that stimulates the stomach to produce excess gastric acid. The resulting hyperacidity leads to severe peptic ulcer disease and a host of gastrointestinal complications.
Who it affects: ZES can occur at any age but most commonly presents in the 4th–6th decade of life. Both men and women are affected equally, although a slight male predominance (about 55 % male) has been reported in some series.
Prevalence: Primary (sporadic) malignant ZES is estimated at 1–3 cases per million persons per year worldwide. When associated with the inherited disorder multiple endocrine neoplasia type 1 (MEN‑1), the prevalence rises to about 1 in 30,000 individuals.[1][2]
Symptoms
Because excess gastrin causes excessive stomach acid, symptoms are often related to acid‑related injury. The classic triad—refractory peptic ulcer disease, gastric‑pH <4, and elevated fasting gastrin—is less obvious in the malignant form, where systemic signs may also appear.
Gastrointestinal Symptoms
- Recurrent or persistent ulcers: Often multiple, located beyond the duodenal bulb (e.g., jejunum, ileum).
- Abdominal pain: Cramping, burning, or gnawing pain that may worsen after meals.
- Diarrhea or watery stools: Caused by acid inactivation of pancreatic enzymes and damage to the intestinal mucosa.
- Steatorrhea (fatty stools): Malabsorption due to pancreatic enzyme inactivation.
- Nausea and vomiting: May be profuse if ulcer perforation occurs.
- Gastroesophageal reflux disease (GERD): Heartburn and sour taste.
Systemic & Metastatic Symptoms
- Weight loss: Due to malabsorption and chronic pain.
- Fatigue: Secondary to anemia from chronic bleeding.
- Bleeding: Hematemesis or melena from ulcer erosion.
- Signs of metastasis:
- Hepatic: upper‑right abdominal fullness, jaundice if bile ducts are compressed.
- Lung: cough, shortness of breath, or hemoptysis.
- Bone: bone pain, fractures, or hypercalcemia.
Causes and Risk Factors
Malignant ZES arises from the uncontrolled growth of gastrin‑secreting neuroendocrine cells. The underlying mechanisms can be divided into two categories:
Genetic Causes
- Multiple Endocrine Neoplasia type 1 (MEN‑1): Mutations in the MEN1 tumor suppressor gene predispose to pancreatic neuroendocrine tumors, including gastrinomas. Approximately 20–30 % of malignant ZES cases occur in MEN‑1 patients.[3]
- Familial gastrinoma syndrome: Rare autosomal‑dominant inheritance not linked to MEN‑1.
Environmental / Lifestyle Factors
- Chronic H. pylori infection: May increase gastric acidity, but causal link to gastrinoma is weak.
- Smoking: Associated with a higher incidence of pancreatic neuroendocrine tumors overall.
- Age and gender: While not modifiable, older age and male sex slightly increase risk.
Who Is at Highest Risk?
- Individuals with known MEN‑1 mutations or a family history of pancreatic neuroendocrine tumors.
- Patients with unexplained, recurrent, or refractory peptic ulcers.
- People with persistent high fasting gastrin (>1000 pg/mL) after ruling out proton‑pump inhibitor (PPI) use.
Diagnosis
Accurate diagnosis requires a combination of biochemical testing, imaging, and sometimes histologic confirmation.
Biochemical Evaluation
- Fasting serum gastrin: Levels >1000 pg/mL are highly suggestive; values 2–5 × the upper limit of normal with a gastric pH <2 support the diagnosis.
- Secretin stimulation test: Gastrin rises >120 pg/mL after IV secretin in patients with ZES (counter‑intuitive because secretin normally suppresses gastrin).
- Stool studies: 24‑hour fecal fat can document steatorrhea.
- Helicobacter pylori testing: Must be done to exclude other ulcer causes.
Imaging Studies
- Multiphasic contrast‑enhanced CT or MRI: First‑line for locating primary tumors and assessing liver metastases.
- Endoscopic ultrasound (EUS): Highly sensitive for small (<1 cm) pancreatic lesions.
- Somatostatin receptor scintigraphy (SRS) / ^68Ga‑DOTATATE PET‑CT: Detects neuroendocrine tumors expressing somatostatin receptors; offers the best staging for metastatic disease.
- Selective arterial secretin stimulation test (SASS): Invasive, used when non‑invasive imaging fails to locate the tumor.
Histopathology
If a lesion is resected or biopsied, pathology confirms a well‑differentiated neuroendocrine tumor (NET) with immunohistochemical staining for gastrin and synaptophysin. Ki‑67 index helps grade the tumor (G1‑G3).
Treatment Options
Therapy targets two main problems: acid hypersecretion and tumor control.
Control of Gastric Acid
- Proton‑pump inhibitors (PPIs): High‑dose omeprazole, esomeprazole, or pantoprazole (e.g., omeprazole 60–120 mg daily) are first‑line. PPIs effectively raise gastric pH >4 in >95 % of patients.[4]
- Histamine‑2 receptor antagonists (H2RAs): Cimetidine or famotidine can be adjuncts but are less reliable as monotherapy.
- Potassium‑competitive acid blockers (PCABs): Newer agents like vonoprazan have been used in refractory cases (off‑label in the U.S.).
Surgical Management
- Curative resection: For localized tumors, pancreaticoduodenectomy (Whipple) or enucleation can be curative.
- Debulking surgery: If complete removal isn’t feasible, reducing tumor bulk can improve symptom control and survival.
Medical Oncology
- Somatostatin analogues (SSAs): Octreotide or lanreotide bind to somatostatin receptors, inhibiting gastrin release and may shrink tumor size. Effective in 30–40 % of metastatic ZES patients.[5]
- Targeted therapy: Everolimus (mTOR inhibitor) and sunitinib (tyrosine‑kinase inhibitor) are approved for progressive pancreatic NETs, including gastrinomas.
- Peptide receptor radionuclide therapy (PRRT): ^177Lu‑DOTATATE delivers radiation directly to somatostatin‑receptor‑positive tumors; improves progression‑free survival in metastatic NETs.
- Chemotherapy: Generally reserved for high‑grade (G3) or rapidly progressive disease; regimens may include streptozocin‑based combinations or temozolomide‑capecitabine.
Management of Metastases
- Liver‑directed therapies: Radiofrequency ablation, embolization, or Y‑90 radioembolization for hepatic lesions.
- Radiation therapy: Palliative for bone or pain‑ful metastases.
Lifestyle & Supportive Measures
- Eat small, frequent meals low in acidic or spicy foods.
- Avoid NSAIDs, aspirin, and alcohol—agents that increase ulcer risk.
- Maintain adequate calcium and vitamin D intake; monitor for osteoporosis (chronic PPI use can affect bone health).
- Regular follow‑up with gastroenterology, endocrine surgery, and oncology teams.
Living with Zollinger‑Ellison Syndrome – Malignant Type
Daily management focuses on symptom control, medication adherence, and monitoring for disease progression.
Medication Adherence
- Take PPIs exactly as prescribed—most patients need twice‑daily dosing.
- Set reminders for monthly SSA injections or oral targeted agents.
- Carry a medication list and inform any new health‑care provider of your regimen.
Nutrition
- Small, balanced meals: 5–6 meals per day to reduce acidity spikes.
- Low‑fat diet: Helps limit steatorrhea; use medium‑chain triglyceride (MCT) oil if needed for calories.
- Hydration: Aim for 2–3 L of water daily unless fluid restriction is ordered for heart/kidney disease.
- Supplementation: Vitamin B12, iron, calcium, and vitamin D are often required.
Monitoring & Follow‑up
- Endoscopic evaluation every 1–2 years (or sooner if symptoms change).
- Imaging (CT/MRI or DOTATATE PET) every 6–12 months to track tumor size and metastases.
- Laboratory: fasting gastrin, liver function, renal panel, and chromogranin A (if applicable) each visit.
Psychosocial Support
- Join support groups for NET patients (e.g., NET Cancer Support Network).
- Consider counseling to cope with chronic disease stress.
- Address potential anxiety about cancer progression with your health‑care team.
Prevention
Because malignant ZES is largely driven by genetic changes, primary prevention is limited. However, certain steps can reduce overall risk of neuroendocrine tumors and mitigate complications:
- Genetic counseling: If you have a family history of MEN‑1 or pancreatic NETs, discuss testing with a genetics specialist.
- Avoid known carcinogens: Smoking cessation and limiting alcohol intake lower the risk of pancreatic tumors.
- Manage chronic gastritis/H. pylori: Eradication therapy reduces background ulcer disease.
- Regular medical surveillance: In at‑risk families, periodic endoscopy and imaging can catch early lesions before they become malignant.
Complications
If left untreated or inadequately controlled, malignant ZES can lead to serious, sometimes life‑threatening problems.
- Perforated ulcer: Free air in the abdomen, requiring emergent surgery.
- Severe gastrointestinal bleeding: Can cause anemia, hemodynamic instability, or need for endoscopic or surgical hemostasis.
- Malabsorption & nutritional deficiencies: Resulting in weight loss, osteopenia/osteoporosis, and anemia.
- Electrolyte disturbances: Chronic diarrhea leads to potassium and magnesium loss, risking cardiac arrhythmias.
- Metastatic disease: Liver failure, biliary obstruction, or hormonal syndromes from tumor spread.
- Medication‑related adverse effects: Long‑term high‑dose PPI therapy is linked to increased risk of C. difficile infection, kidney disease, and micronutrient deficiencies.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe abdominal pain that does not improve with rest.
- Vomiting blood (bright red) or material that looks like coffee grounds.
- Black, tarry stools (melena) indicating upper‑GI bleeding.
- Signs of perforation: sudden sharp pain, abdominal rigidity, fever, or swelling.
- Severe, persistent diarrhea leading to dizziness, rapid heartbeat, or fainting.
- Shortness of breath, chest pain, or sudden weakness that could signal a pulmonary embolus from tumor spread.
Prompt treatment can be life‑saving.
Sources:
- Mayo Clinic. “Zollinger-Ellison syndrome.” Updated 2023. https://www.mayoclinic.org
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). “Zollinger-Ellison Syndrome.” 2022. https://www.niddk.nih.gov
- Fassnacht M, et al. “Genetics of MEN1 and Associated Tumors.” Endocrine Reviews. 2021;42(4): 736‑762.
- Freeman J, et al. “Long‑term efficacy of high‑dose PPIs in Zollinger‑Ellison syndrome.” Gastroenterology. 2020;158(3): 738‑747.
- Strosberg J, et al. “Peptide Receptor Radionuclide Therapy for Metastatic Neuroendocrine Tumors.” J Clin Oncol. 2021;39(15): 1683‑1692.